DexCom, Inc. vs T-Mobile Us Inc — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while T-Mobile Us Inc trades at $148.75 (market cap $183.76B). The key difference: T-Mobile Us Inc is far larger — about 5.8× DexCom, Inc.'s market cap, and T-Mobile Us Inc pays a 2.73% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and T-Mobile Us Inc for 84 Days on average.
| DXCM | TMUS | |
|---|---|---|
Market Cap | $31.86B | $183.76B |
Volume | 3,607,070 | 4,294,650 |
Sector | Health | Media |
52-Week High | $92.34 | $230.06 |
52-Week Low | $54.84 | $161.73 |
Typical Hold Time | 62 Days | 84 Days |
Enterprise Value | $31.32B | $300.37B |
Dividend Yield | — | 2.73% |
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
T-Mobile (TMUS) is trading at $149.79, down 10.64% in the last session. The stock shows strong fundamentals with revenue growth from $81.4B in 2024 to $88.3B in 2025 and robust profitability (net margin 11.45%). Recent technical indicators are mixed with a bearish moving average signal but neutral oscillators. The company announced a 15% dividend increase and is advancing AI-powered 5G network capabilities. Analyst consensus remains strongly bullish with 79.6% buy ratings and a $231.10 price target.
TMUS presents a compelling growth story with solid financials and strategic initiatives, though elevated debt levels and competitive pressures pose risks. The current price decline may offer an entry point given the significant upside to analyst targets, supported by consistent earnings beats and dividend growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →